Stockscreener 앱 받기
9.52
0.52%
-0.05
시장 영업 전:
8.40
-1.12
-11.76%
전일 마감가:
$9.57
열려 있는:
$9.72
하루 거래량:
1.44M
Relative Volume:
0.55
시가총액:
$1.68B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-2.6742
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
-6.30%
1개월 성능:
-20.40%
6개월 성능:
-59.59%
1년 성능:
-73.02%
1일 변동 폭
$9.51
$9.925
1주일 범위
$9.51
$10.74
52주 변동 폭
$6.36
$47.45
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.52 | 1.68B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Dyne Therapeutics (DYN) Receives Continued Buy Rating from Guggenheim | DYN Stock News - GuruFocus
Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade (DYN) - Seeking Alpha
Dyne Therapeutics (DYN): Baird Lowers Price Target to $32 | DYN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent
Dyne at ‘attractive entry point’ following pullback, says Chardan - Yahoo Finance
Dyne Therapeutics (DYN) Price Target Reduced by Baird | DYN Stoc - GuruFocus
H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock - Investing.com
Dyne adjusts regulatory timeline for DYNE-101 after FDA feedback - The Pharma Letter
Dyne’s DM1 treatment receives FDA breakthrough designation By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revi - GuruFocus
Dyne Therapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – DYN - Business Wire
Dyne Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Dyne Therapeutics (DYN) Boosted by DYNE-101 Program Updates | DY - GuruFocus
Dyne Therapeutics (DYN) Rating and Price Target Maintained by Ch - GuruFocus
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Benzinga
Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | D - GuruFocus
Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathw - GuruFocus
Transcript : Dyne Therapeutics, Inc.Special Call - MarketScreener
Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathway Update | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Faces Setback with DYNE-101 Approval Del - GuruFocus
Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revision | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Shares Drop Amid Clinical Trial Revision | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | DYN Stock News - GuruFocus
Dyne stock on revised plan for clinical program (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics (DYN) Gains FDA Breakthrough Therapy Designati - GuruFocus
Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy - MarketScreener
Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1 - Investing.com Nigeria
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Granted Breakthrough Therapy Designation - TipRanks
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - The Manila Times
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol Elevating vHOT as Primary Endpoint for U.S. Accelerated Approval of DYNE-101 in Myotonic Dystrophy Type 1 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
FDA Breakthrough: Dyne's DM1 Drug Shows 20% Muscle Strength Gain in Latest Trial Data - Stock Titan
Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire
Dyne Therapeutics To Host Investor Conference Call And Webcast - marketscreener.com
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET | DYN Stock News - GuruFocus
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - GlobeNewswire
Dyne Therapeutics to Reveal Crucial Data on DYNE-101 DM1 Treatment: Key Clinical Updates Coming Tomorrow - Stock Titan
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: FDA - openPR.com
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Raymond James - Defense World
Dyne Therapeutics (DYN) Receives "Outperform" Rating by Raymond James | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN): Analyst Sets Positive Outlook with $37 Price Target | DYN Stock News - GuruFocus
Dyne Therapeutics officer sells shares worth $1,949 By Investing.com - Investing.com Canada
Dyne Therapeutics officer sells shares worth $1,949 - Investing.com
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Millennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com
Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire
Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.23%
자본화:
|
볼륨(24시간):